Home / Market News / $GILD
benzinga Corporate Catalyst Impact 55/100 ● positive

JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

Oct 7, 2026, 4:35 PM UTC · Primary ticker $GILD

JP Morgan has reiterated its 'Overweight' rating on Gilead Sciences and increased its price target from $160 to $170. This indicates a positive outlook from a major investment bank, potentially boosting investor confidence in GILD.

JP Morgan analyst Chris Schott has maintained an 'Overweight' rating on Gilead Sciences and raised the price target from $160 to $170. This action signals continued confidence from a prominent financial institution in Gilead's future performance. For traders, this could lead to short-term positive momentum for GILD stock as investors react to the upgraded outlook. The long-term implication is a reinforced positive sentiment, potentially attracting more institutional investment. A key opportunity for traders is to capitalize on any immediate upward price movement, while the risk lies in whether the market has already priced in such analyst upgrades or if other fundamental factors might outweigh this positive news.

$GILD positive Price target increase and maintained overweight rating
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.